These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 1310556

  • 1. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.
    Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB.
    Virology; 1992 Mar; 187(1):189-201. PubMed ID: 1310556
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
    Hu LF, Chen F, Altiok E, Winberg G, Klein G, Ernberg I.
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
    Tierney RJ, Steven N, Young LS, Rickinson AB.
    J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
    Brooks L, Yao QY, Rickinson AB, Young LS.
    J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
    [Abstract] [Full Text] [Related]

  • 6. Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells.
    Wolf J, Pawlita M, Klevenz B, Frech B, Freese UK, Müller-Lantzsch N, Diehl V, zur Hausen H.
    Int J Cancer; 1993 Feb 20; 53(4):621-7. PubMed ID: 8382194
    [Abstract] [Full Text] [Related]

  • 7. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    Gregory CD, Rowe M, Rickinson AB.
    J Gen Virol; 1990 Jul 20; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
    [Abstract] [Full Text] [Related]

  • 8. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
    Nilsson T, Sjöblom A, Masucci MG, Rymo L.
    Virology; 1993 Apr 20; 193(2):774-85. PubMed ID: 8384755
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
    Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS.
    J Exp Med; 1993 Feb 01; 177(2):339-49. PubMed ID: 8381153
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
    Puglielli MT, Woisetschlaeger M, Speck SH.
    J Virol; 1996 Sep 01; 70(9):5758-68. PubMed ID: 8709191
    [Abstract] [Full Text] [Related]

  • 12. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes.
    Schaefer BC, Woisetschlaeger M, Strominger JL, Speck SH.
    Proc Natl Acad Sci U S A; 1991 Aug 01; 88(15):6550-4. PubMed ID: 1713681
    [Abstract] [Full Text] [Related]

  • 13. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes.
    Finke J, Fritzen R, Ternes P, Trivedi P, Bross KJ, Lange W, Mertelsmann R, Dölken G.
    Blood; 1992 Jul 15; 80(2):459-69. PubMed ID: 1378321
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
    Ernberg I, Falk K, Minarovits J, Busson P, Tursz T, Masucci MG, Klein G.
    J Gen Virol; 1989 Nov 15; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.
    Blood; 1995 Jul 15; 86(2):659-65. PubMed ID: 7605996
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.
    Taylor KA, Wetzel S, Lyles DS, Pollok BA.
    J Virol; 1994 Oct 15; 68(10):6421-31. PubMed ID: 8083980
    [Abstract] [Full Text] [Related]

  • 20. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
    Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB.
    J Virol; 1992 Jan 15; 66(1):122-31. PubMed ID: 1309242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.